Coming Soon: New PT Program for the Detection of SARS CoV-2

In the wake of the global outbreak of COVID-19, clinical laboratories have shown an unwavering commitment to the patients they serve by ramping up efforts to deploy COVID-19 testing. The CAP is committed to supporting your efforts and is happy to announce a new proficiency testing (PT) program for the detection of SARS CoV-2 by nucleic acid amplification testing.

An important element of the CAP’s new program development process is to pilot test PT programs with a set of laboratories prior to the first mailings. This allows us to verify specimen performance across the multiple methods and testing platforms utilized by our customers, and ensures we are providing you with the highest quality program. We are actively pilot testing our new PT program for COVID-19 testing and anticipate successful results. We will make this new program available for your laboratory to order soon.

Program information for SARS CoV-2, Molecular (COV2)

- Samples are non-infectious and target CDC and WHO consensus gene sequences N, E, RdRP, and ORF1a
- Allows laboratories to assess their entire workflow from nucleic acid extraction through detection
- First mailing of the program will be in spring 2020 with a second mailing later in the year

We look forward to sharing with you soon more details regarding how to order the new SARS CoV-2, molecular program. In the meantime, visit cap.org for the latest COVID-19 information and updates.